Stock CATX PERSPECTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Perspective Therapeutics, Inc. Stock

Equities

CATX

US46489V1044

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX
Other stock markets
 12:32:23 2024-05-08 pm EDT 		5-day change 1st Jan Change
1.765 USD -4.08% Intraday chart for Perspective Therapeutics, Inc. +2.94% +335.32%
Apr. 30 Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry CI
Apr. 18 Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2024 * - Sales 2025 * 63K Capitalization 1.08B
Net income 2024 * -48M Net income 2025 * -52M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 17,142 x
P/E ratio 2024 *
-21.2 x
P/E ratio 2025 *
-17.8 x
Employees 118
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.58%
More Fundamentals * Assessed data

Chart Perspective Therapeutics, Inc.

Dynamic Chart

Latest news about Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry CI
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating MT
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Markets Steady -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study MT
Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma CI
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors CI
Sector Update: Health Care Stocks Softer in Afternoon Trading MT
Perspective Therapeutics to Raise $87.4 Million in Private Placement MT
More news

Latest transcript on Perspective Therapeutics, Inc.

Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. - Analyst/Investor Day
More transcripts

Analyst Recommendations on Perspective Therapeutics, Inc.

B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating MT
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack MT
JonesTrading Initiates Perspective Therapeutics With Buy Rating, $1.40 Price Target MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.20 From $1, Maintains Outperform Rating MT
More recommendations

Press releases Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate at Upcoming May Investor Conferences AQ
Perspective Therapeutics to Participate at Upcoming May Investor Conferences GL
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results GL
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs GL
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs AQ
More press releases

Quotes and Performance

1 day+0.55%
1 week+9.52%
Current month+9.52%
1 month+24.32%
3 months+103.49%
6 months+581.48%
Current year+357.71%
More quotes

Highs and lows

1 week
1.71
Extreme 1.71
1.90
1 month
1.29
Extreme 1.29
1.90
Current year
0.38
Extreme 0.3799
1.90
1 year
0.21
Extreme 0.205
1.90
3 years
0.19
Extreme 0.1922
1.90
5 years
0.19
Extreme 0.1922
2.81
10 years
0.19
Extreme 0.1922
3.79
More quotes

Managers and Directors - Perspective Therapeutics, Inc.

Managers TitleAgeSince
Johan Spoor CEO
 Chief Executive Officer 52 23-02-02
Mark Austin DFI
 Director of Finance/CFO 37 17-06-30
Jonathan Hunt DFI
 Director of Finance/CFO 57 23-02-02
Members of the board TitleAgeSince
Heidi Henson BRD
 Director/Board Member 58 23-05-31
Lori Woods CHM
 Chairman 61 23-02-02
Robert Williamson BRD
 Director/Board Member 58 23-02-02
More insiders

Quotes

Date Price Change Volume
24-05-08 1.745 -5.16% 1 388 237
24-05-07 1.84 +0.55% 3,917,512
24-05-06 1.83 +1.10% 2,971,983
24-05-03 1.81 +4.62% 4,706,901
24-05-02 1.73 +1.76% 6,888,919

Delayed Quote Nyse, May 07, 2024 at 04:00 pm EDT

More quotes

Company Profile

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-05-13 - Guggenheim Healthcare Talks Radiopharmaceuticals Day - Panel
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.84 USD
Average target price
1.775 USD
Spread / Average Target
-3.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
PERSPECTIVE THERAPEUTICS, INC. Stock Perspective Therapeutics, Inc.
+357.71% 1.08B
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.54% 185B
MEDTRONIC PLC Stock Medtronic plc
-0.58% 109B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-2.74% 68.54B
DEXCOM, INC. Stock DexCom, Inc.
+4.84% 51.74B
CENCORA, INC. Stock Cencora, Inc.
+10.40% 45.22B
HOYA CORPORATION Stock Hoya Corporation
+3.12% 41.74B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.87% 26.69B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+4.61% 26.83B
TERUMO CORPORATION Stock Terumo Corporation
+11.62% 25.63B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. CATX Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW